NYC, May 24, 2025 (GLOBE NEWSWIRE) — NEW YORK, May 24, 2025 / GlobeNewswire/ — ...

Vigil Neuroscience Inc ( ($VIGL) ) just unveiled an announcement. On May 22, 2025, Vigil Neuroscience, Inc. held its Annual Meeting of ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Here's a recap of the week’s most important stories.

Sanofi to acquire clinical-stage biotechnology company, Vigil Neuroscience for $470 million: Paris Friday, May 23, 2025, 11:00 Hrs [IST] Sanofi, an innovative global healthcare co ...

French pharma Sanofi has acquired the U.S.-based biotech firm Vigil Neuroscience for $470 million, aiming to bolster its ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

Sanofi SA made good on its plan to bear down on M&A by agreeing to buy Vigil Neuroscience Inc. for $8 per share (NASDAQ:VIGL). Included in the transaction is a non-tradeable contingent value right ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...